201 related articles for article (PubMed ID: 21630605)
1. Dermatological side effects of current and upcoming targeted therapies in oncology.
Bonny M; Buyse V; Brochez L
Acta Clin Belg; 2011; 66(2):97-103. PubMed ID: 21630605
[TBL] [Abstract][Full Text] [Related]
2. Molecular targeted therapies for solid tumors: management of side effects.
Grünwald V; Soltau J; Ivanyi P; Rentschler J; Reuter C; Drevs J
Onkologie; 2009 Mar; 32(3):129-38. PubMed ID: 19295254
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management.
Manousaridis I; Mavridou S; Goerdt S; Leverkus M; Utikal J
J Eur Acad Dermatol Venereol; 2013 Jan; 27(1):11-8. PubMed ID: 22540151
[TBL] [Abstract][Full Text] [Related]
4. [Management of adverse effects of targeted therapy toxicities in oncology].
Coquan E; Henri P; de Raucourt S; Lireux B; Lamy E; Delcambre C; Sevin E; Dutriaux C; Bouhier-Leporrier K; Gervais R; Joly F
Rev Prat; 2012 Jan; 62(1):17-25. PubMed ID: 22335060
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous side-effects of kinase inhibitors and blocking antibodies.
Robert C; Soria JC; Spatz A; Le Cesne A; Malka D; Pautier P; Wechsler J; Lhomme C; Escudier B; Boige V; Armand JP; Le Chevalier T
Lancet Oncol; 2005 Jul; 6(7):491-500. PubMed ID: 15992698
[TBL] [Abstract][Full Text] [Related]
6. Dermatologic adverse events to chemotherapeutic agents, Part 2: BRAF inhibitors, MEK inhibitors, and ipilimumab.
Choi JN
Semin Cutan Med Surg; 2014 Mar; 33(1):40-8. PubMed ID: 25037257
[TBL] [Abstract][Full Text] [Related]
7. Dermatological toxicity associated with targeted therapies in cancer: optimal management.
Peuvrel L; Dréno B
Am J Clin Dermatol; 2014 Oct; 15(5):425-44. PubMed ID: 25117153
[TBL] [Abstract][Full Text] [Related]
8. Adverse events of targeted therapies.
Klastersky JA
Curr Opin Oncol; 2014 Jul; 26(4):395-402. PubMed ID: 24825019
[TBL] [Abstract][Full Text] [Related]
9. Skin adverse events in recently approved targeted therapies in solid malignancies.
Habre M; Salloum A; Habre SB; Abi Chebl J; Dib R; Kourie HR
Future Oncol; 2019 Jan; 15(3):331-343. PubMed ID: 30523696
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane.
Macdonald JB; Macdonald B; Golitz LE; LoRusso P; Sekulic A
J Am Acad Dermatol; 2015 Feb; 72(2):203-18; quiz 219-20. PubMed ID: 25592338
[TBL] [Abstract][Full Text] [Related]
11. Targeted agents: management of dermatologic toxicities.
Burtness B
J Natl Compr Canc Netw; 2014 May; 12(5 Suppl):793-6. PubMed ID: 24853219
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous reactions related to systemic immunomodulators and targeted therapeutics.
Hammond-Thelin LA
Dermatol Clin; 2008 Jan; 26(1):121-59, ix. PubMed ID: 18023775
[TBL] [Abstract][Full Text] [Related]
13. Skin moisturization for xerosis related to targeted anticancer therapies.
Gisondi P; Girolomoni G
J Am Acad Dermatol; 2015 Jul; 73(1):e33. PubMed ID: 26089072
[No Abstract] [Full Text] [Related]
14. Reply to: "Skin moisturization for xerosis related to targeted anticancer therapies".
Valentine J; Belum VR; Duran J; Ciccolini K; Schindler K; Wu S; Lacouture ME
J Am Acad Dermatol; 2015 Jul; 73(1):e35-6. PubMed ID: 26089073
[No Abstract] [Full Text] [Related]
15. [Appearance of skin and nail toxicity in patients with breast cancer who underwent trastuzumab-containing chemotherapy].
Adachi S; Yoshimura T; Matsuoka T; Okada K; Yasuda T; Kamei K
Gan To Kagaku Ryoho; 2011 Sep; 38(9):1453-6. PubMed ID: 21918340
[TBL] [Abstract][Full Text] [Related]
16. Insights into the pathophysiology and management of dermatologic toxicities to EGFR-targeted therapies in colorectal cancer.
Lacouture ME
Cancer Nurs; 2007; 30(4 Suppl 1):S17-26. PubMed ID: 17666987
[TBL] [Abstract][Full Text] [Related]
17. Managing Cutaneous Side Effects From Targeted Molecular Inhibitors for Melanoma and Nonmelanoma Skin Cancer.
Tang N; Ratner D
Dermatol Surg; 2016 Jan; 42 Suppl 1():S40-8. PubMed ID: 26730973
[TBL] [Abstract][Full Text] [Related]
18. Incidence and risk of xerosis with targeted anticancer therapies.
Valentine J; Belum VR; Duran J; Ciccolini K; Schindler K; Wu S; Lacouture ME
J Am Acad Dermatol; 2015 Apr; 72(4):656-67. PubMed ID: 25637330
[TBL] [Abstract][Full Text] [Related]
19. [Dermatologic adverse events of the new targeted anticancer therapies used in oncodermatology].
Sibaud V; Delord JP; Chevreau C; Gangloff D; Garrido-Stowhas I
Ann Chir Plast Esthet; 2012 Apr; 57(2):106-13. PubMed ID: 22425393
[TBL] [Abstract][Full Text] [Related]
20. Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology.
Grávalos C; Sanmartín O; Gúrpide A; España A; Majem M; Suh Oh HJ; Aragón I; Segura S; Beato C; Botella R
Clin Transl Oncol; 2019 May; 21(5):556-571. PubMed ID: 30284232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
